Effects of PKF 115–584 on cell proliferation.

Sachiko Matsuzaki (405488), Claude Darcha (405489)
2015 · doi:10.1371/journal.pone.0061690.g001 · W6923023966
other OA: green CC0
🔓 Open OA copy Full text JSON View on OpenAlex View at publisher
⚙ AI-generated deep summary by qwen3.7-flash, 2026-09-11 · read from full text ⓘ

The study investigated the in vitro effects of PKF 115–584, a small-molecule antagonist of the Tcf/ß-Catenin complex, on cell proliferation within endometrial epithelial and stromal cells. Researchers compared these effects between patients with endometriosis and those without across various menstrual phases, measuring basal proliferation rates and the percentage of inhibition following treatment. The results demonstrated that PKF 115–584 inhibited cell proliferation in both cell types, with significant differences observed in basal proliferation levels between the two patient groups depending on the menstrual phase. This paper is centrally about endometriosis — specifically examining how inhibiting the Wnt signaling pathway affects the growth of endometrial tissue in patients with the condition.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

A, B: Basal cell proliferation in non-treated endometrial epithelial (A) and stromal (B) cells of patients with and without endometriosis. C, D: Percent inhibition of cell proliferation in endometrial epithelial (C) and stromal (D) cells of patients with and without endometriosis treated with PKF 115–584. Results are presented as the mean+SEM. Basal cell proliferation is presented as OD. Percent inhibition of cell proliferation is calculated as percent of vehicle control. M: menstrual phase, P: proliferative phase, ES: early secretory phase, MS: mid- secretory phase, LS: late secretory phase. Endo (+): Endometrium of patients with endometriosis (M: n = 6, P: n = 20, ES: n = 7, MS: n = 15, LS: n = 6). Endo (–): endometrium of patients without endometriosis (M: n = 4, P: n = 11, ES: n = 8, MS: n = 8, LS: n = 4). a: p<.05 versus patients without endometriosis.
Full text 1,071 characters · extracted from oa-doi-fallback · click to expand
In Vitro Effects of a Small-Molecule Antagonist of the Tcf/ß-Catenin Complex on Endometrial and Endometriotic Cells of Patients with Endometriosis Figure 1 Effects of PKF 115–584 on cell proliferation. A, B: Basal cell proliferation in non-treated endometrial epithelial (A) and stromal (B) cells of patients with and without endometriosis. C, D: Percent inhibition of cell proliferation in endometrial epithelial (C) and stromal (D) cells of patients with and without endometriosis treated with PKF 115–584. Results are presented as the mean+SEM. Basal cell proliferation is presented as OD. Percent inhibition of cell proliferation is calculated as percent of vehicle control. M: menstrual phase, P: proliferative phase, ES: early secretory phase, MS: mid- secretory phase, LS: late secretory phase. Endo (+): Endometrium of patients with endometriosis (M: n = 6, P: n = 20, ES: n = 7, MS: n = 15, LS: n = 6). Endo (–): endometrium of patients without endometriosis (M: n = 4, P: n = 11, ES: n = 8, MS: n = 8, LS: n = 4). a: p<.05 versus patients without endometriosis.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-05-11T08:48:50.894309+00:00
License: CC0 · commercial use OK